BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global Unmet Medical Needs : Available, Affordable, Sustainable.
BioSourcing changes the design paradigm of these new biotherapeutics thanks to the mastery of several breakthrough technologies including genome editing (CRISPR).
The BioSourcing disruptive approach leads to a drastic reduction in capital requirements and production costs, especially for large volumes, as well as an improvement in the quality/efficiency of biopharmaceuticals through better glycosylation.
The technological approach developed by BioSourcing has already given rise to biotherapeutics approved by the health industry and regulatory bodies (FDA, EMA).
BioSourcing strongly contributes to sustainable development, in particular in drastically reducing the carbon footprint.
BioSourcing is a fully operational biotechnology company, based in Liège, Belgium. Its team is made up of the best scientists, international experts in their field and has developed strategic partnerships with leaders in the pharmaceutical and biotechnology industry.
Products & Services
BioSourcing is developing a pipeline of 6 biosimilars, including 5 monoclonal antibodies, with very high commercial potential belonging to the WHO list of essential medicines.
The creation of the founding lines has begun and thanks to the disruptive technologies developed by BioSourcing, production volumes of several hundred kg are possible with COGs 2 to 5 times lower than the current COGs in the industry, while drastically limiting CAPEX. The first Kg of Drug substance will be available within 2 years for entry into the clinical phase.
The technological approach developed by BioSourcing has already given rise to biotherapeutics approved by the health industry and regulatory bodies (FDA, EMA).
BioSourcing offers worldwide or regional development and commercialization partnerships for its biosimilars, including technology transfer for local productions.
Contact
Email: contact@bio-sourcing.com
Website
